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The mTOR kinase (mammalian Target of Rapamycin) is a major 
regulatory hub that senses and integrates nutrient, energy and growth 
factor inputs to promote cell growth. In this issue of EMBO Reports, 
Byun and colleagues report that high intracellular levels of lactate 
activate mTORC1 in KRAS transformed cells independently of a growth 
factor input [1]. This suggests a mechanism for how mTORC1 can be co-
opted to support oncogenic growth and proliferation. 
 
Lactate production is increased in many tumors as a consequence of the 
Warburg effect, where cancer cells generate ATP preferentially via glycolysis 
despite the availability of oxygen. Lactate is the metabolic end product of 
glycolysis and is often dismissed as an unwanted byproduct that is discarded 
from the cell. However, recent studies have revealed an active role for lactate 
in cancer metabolism. There are several scenarios where tumor cells utilise 
lactate as a carbon source. For example, in the case of metabolic symbiosis, 
lactate generated in the inner, hypoxic core of a tumor is utilised by cells in 
the periphery of the tumor where oxygen levels are sufficient to support the 
back conversion of lactate to pyruvate for mitochondrial respiration. In the so-
called reverse Warburg effect, non-transformed stromal cells are stimulated 
by tumor cells to produce lactate which is then taken up and utilised by tumor 
cells (reviewed in 2). There are also tumors where circulating lactate is taken 
up as a metabolic fuel [3]. 
 In this issue, Byun and colleagues report another interesting aspect of 
lactate in oncogenic growth. Starting from KRAS transformed MEF cells, they 
observed KRAS-MEK induced overexpression of COUP-TFII (chicken 
ovalbumin upstream promoter transcription factor). COUP-TFII upregulates 
LDHA (lactate dehydrogenase), the enzyme catalyzing the terminal step of 
glycolysis which converts pyruvate to lactate. Thus far, these observations 
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follow the well-established sequence of events in cancer where oncogenic 
transformation is accompanied by a global metabolic shift to aerobic 
glycolysis with a concomitant increase in lactate production. The novel and 
striking finding reported by Byun et al. is that lactate is an activator of 
mTORC1 (mTOR Complex 1). mTORC1 positively regulates translation and 
various other anabolic pathways to support cell growth and proliferation. 
Evidence for a direct role of lactate in mTORC1 activation is the observation 
that exogenous lactate rescues mTORC1 signaling upon knockdown of 
COUP-TFII or LDHA. The mechanism described for lactate-mediated 
mTORC1 activation involves perturbation of negative regulation upstream of 
mTORC1. The small G-protein Rheb, in its GTP-bound form, activates 
mTORC1 on the surface of the lysosome (Fig. 1). The GTPase activating 
complex TSC (composed of the TSC1 and TSC2 proteins) negatively 
regulates Rheb-GTP and thus inactivates mTORC1 signaling. Byun et al. 
observed that high levels of exogenous lactate (20mM) disrupt the binding of 
TSC to Rheb-GTP thereby preserving Rheb-GTP levels. Exogenous lactate 
also inhibits translocation of TSC (visualized by TSC2) to the lysosomal 
surface where it would normally encounter and inhibit Rheb-GTP. Thus, 
lactate sustains constitutively high levels of active Rheb and, in turn, 
constitutively active mTORC1. Although surprising, this is consistent with a 
recent report showing that autophagy, which is suppressed by mTORC1, can 
be inhibited by lactate [4]. Lactate administration has also been shown to 
activate mTORC1 in muscle of adult mice [5]. 
 What are the implications of this study? Lactate overproduction is 
seemingly more frequent in cancers than mTORC1 hyperactivation. 
Presumably, there is a threshold for the concentration of intracellular lactate 
required for mTORC1 activation. Intracellular lactate is exported from cells by 
the ubiquitous MCT1 (monocarboxylate transporter) and by the hypoxia-
induced MCT4 isoform whose expression is frequently induced in tumors. 
Thus, depending on the levels of MCT1 and MCT4 expression, tumors differ 
in their lactate exporting capacity and thereby in their ability to accumulate 
intracellular lactate to levels required for mTORC1 activation. Few data are 
available on intracellular lactate concentrations in tumors to confirm this 
assumption. Nevertheless, as an MCT1 inhibitor (AZD3965) is currently in 
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clinical trials for cancer [6], it would be of interest to ascertain if high 
intracellular lactate levels may have the undesired effect of stimulating 
mTORC1 in patient tumors. 
 Conversely, mTORC1 activation is encountered in cancers where none 
of its negative regulators (TSC and PTEN) are mutated. These negative 
regulators are upstream of Rheb. In these cases, it is possible that mTORC1 
is activated by lactate blocking TSC action. Again, this can be addressed by 
determining the intracellular lactate concentration in tumors. 
 Are there normal physiological conditions where lactate could serve as 
an mTORC1 activator? Upon stimulation, T-cells go through a short phase of 
rapid proliferation. As in cancer, this rapid proliferation is characterized by a 
shift to aerobic glycolysis to generate ATP and biosynthetic precursors for 
formation of new cells. The increase in glycolysis could also serve to produce 
lactate to sustain mTORC1 activation. Indeed, T-cell activation is exquisitely 
sensitive to rapamycin (IC50 ~0.05nM, substantially below that required in 
other cells) [7], suggesting that maintaining mTORC1 activity is critically 
important in T-cell activation. However, it should be noted that T-cell 
proliferation is blocked by MCT1 inhibition (which should result in even higher 
intracellular lactate levels and mTORC1 activation) [8]. 
 Lactate is receiving belated recognition as being more than an 
unwanted end-product of glycolysis. It is also a source of metabolic fuel and a 
signaling molecule in its own right [9]. The central finding of this study, namely 
that lactate activates mTORC1, has important implications for cancer biology 
and beyond. 
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Figure legends 
 
Figure 1: High intracellular levels of lactate activates mTORC1 by relieving 
TSC repression of Rheb. 
 
Left panel: Under normal physiological conditions mTORC1 is tightly 
regulated. mTORC1 is activated by Rheb. Rheb itself is negatively regulated 
by TSC. TSC is in turn repressed by intracellular cues that sense when 
conditions are favorable for cell growth. Right panel: Highly glycolytic 
conditions generate large amounts of lactate. When intracellular lactate levels 
exceed a certain threshold, it prevents TSC from interacting with Rheb leading 
to constitutive mTORC1 activity. 
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Figure 1 High intracellular levels of lactate activates mTORC1 by relieving 
TSC repression of Rheb. 
Left panel, under normal physiological conditions mTORC1 is tightly 
regulated. mTORC1 is activated by Rheb. Rheb itself is negatively regulated 
by TSC. TSC is in turn repressed by intracellular cues that sense when 
conditions are favorable for cell growth. Right panel, highly glycolytic 
conditions generate large amounts of lactate. When intracellular lactate levels 
exceed a certain threshold, it prevents TSC from interacting with Rheb leading 
to constitutive mTORC1 activity. 
 
